Joel C Sunshine

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2388526/publications.pdf

Version: 2024-02-01

46 papers	5,020 citations	236925 25 h-index	276875 41 g-index
49 all docs	49 docs citations	49 times ranked	8451 citing authors

#	Article	IF	Citations
1	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. New England Journal of Medicine, 2016, 374, 2542-2552.	27.0	1,048
2	Using Intake Biomarkers to Evaluate the Extent of Dietary Misreporting in a Large Sample of Adults: The OPEN Study. American Journal of Epidemiology, 2003, 158, 1-13.	3.4	856
3	PD-1/PD-L1 inhibitors. Current Opinion in Pharmacology, 2015, 23, 32-38.	3.5	483
4	Gold, Poly(Î²-amino ester) Nanoparticles for Small Interfering RNA Delivery. Nano Letters, 2009, 9, 2402-2406.	9.1	258
5	Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells. Biomaterials, 2014, 35, 269-277.	11.4	206
6	Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 237-246.	3.3	172
7	Biodegradable Nanoellipsoidal Artificial Antigen Presenting Cells for Antigen Specific Tâ€Cell Activation. Small, 2015, 11, 1519-1525.	10.0	148
8	Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7769-E7777.	7.1	145
9	Non-viral gene delivery nanoparticles based on Poly(Î²-amino esters) for treatment of glioblastoma. Biomaterials, 2011, 32, 5402-5410.	11.4	133
10	Uptake and Transfection with Polymeric Nanoparticles Are Dependent on Polymer End-Group Structure, but Largely Independent of Nanoparticle Physical and Chemical Properties. Molecular Pharmaceutics, 2012, 9, 3375-3383.	4.6	133
11	Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. , 2018, 6, 99.		129
12	PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison. Clinical Cancer Research, 2017, 23, 4938-4944.	7.0	120
13	Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. Science, 2021, 372, .	12.6	114
14	Smallâ€Molecule Endâ€Groups of Linear Polymer Determine Cellâ€type Geneâ€Delivery Efficacy. Advanced Materials, 2009, 21, 4947-4951.	21.0	105
15	Effects of Base Polymer Hydrophobicity and End-Group Modification on Polymeric Gene Delivery. Biomacromolecules, 2011, 12, 3592-3600.	5.4	102
16	Biomimetic particles as therapeutics. Trends in Biotechnology, 2015, 33, 514-524.	9.3	93
17	The relationship between terminal functionalization and molecular weight of a gene delivery polymer and transfection efficacy in mammary epithelial 2-D cultures and 3-D organotypic cultures. Biomaterials, 2010, 31, 8088-8096.	11.4	83
18	Poly(Î²-Amino Ester)-Nanoparticle Mediated Transfection of Retinal Pigment Epithelial Cells In Vitro and In Vivo. PLoS ONE, 2012, 7, e37543.	2.5	82

#	Article	IF	Citations
19	The Effect and Role of Carbon Atoms in Poly(Î²-amino ester)s for DNA Binding and Gene Delivery. Journal of the American Chemical Society, 2013, 135, 6951-6957.	13.7	72
20	Differential Polymer Structure Tunes Mechanism of Cellular Uptake and Transfection Routes of Poly(Î²-amino ester) Polyplexes in Human Breast Cancer Cells. Bioconjugate Chemistry, 2014, 25, 43-51.	3.6	72
21	Anatomical structures, cell types and biomarkers of the Human Reference Atlas. Nature Cell Biology, 2021, 23, 1117-1128.	10.3	68
22	Nanoengineering approaches to the design of artificial antigen-presenting cells. Nanomedicine, 2013, 8, 1173-1189.	3.3	67
23	Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis. Expert Opinion on Drug Delivery, 2011, 8, 485-504.	5.0	53
24	Advances in polymeric and inorganic vectors for nonviral nucleic acid delivery. Therapeutic Delivery, 2011, 2, 493-521.	2.2	49
25	Gene delivery nanoparticles specific for human microvasculature and macrovasculature. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 1200-1207.	3.3	38
26	Somatic hypermutation and VH gene usage in hairy cell leukaemia. British Journal of Haematology, 2006, 133, 504-512.	2.5	35
27	Clinical, morphologic, and genomic findings in ROS1 fusion Spitz neoplasms. Modern Pathology, 2021, 34, 348-357.	5.5	22
28	Anisotropic biodegradable lipid coated particles for spatially dynamic protein presentation. Acta Biomaterialia, 2018, 72, 228-238.	8.3	20
29	Melanocytic Neoplasms With MAP2K1 in Frame Deletions and Spitz Morphology. American Journal of Dermatopathology, 2020, 42, 923-931.	0.6	19
30	High-throughput evaluation of polymeric nanoparticles for tissue-targeted gene expression using barcoded plasmid DNA. Journal of Controlled Release, 2021, 337, 105-116.	9.9	18
31	BRAF fusion Spitz neoplasms; clinical morphological, and genomic findings in six cases. Journal of Cutaneous Pathology, 2020, 47, 1132-1142.	1.3	17
32	Completing the Circuit:Â Direct-Observe13C,15N Double-Quantum Spectroscopy Permits Sequential Resonance Assignments near a Paramagnetic Center in Acireductone Dioxygenase. Journal of the American Chemical Society, 2008, 130, 2156-2157.	13.7	14
33	A Series of RET Fusion Spitz Neoplasms With Plaque-Like Silhouette and Dyscohesive Nesting of Epithelioid Melanocytes. American Journal of Dermatopathology, 2021, 43, 243-251.	0.6	8
34	Immunoglobulin light chain repertoire in hairy cell leukemia. Leukemia Research, 2007, 31, 1231-1236.	0.8	7
35	Successful Treatment of In-Transit Metastatic Melanoma in a Renal Transplant Patient With Combination T-VEC/Imiquimod Immunotherapy. Journal of Immunotherapy, 2020, 43, 149-152.	2.4	5
36	Immune cell subsets in interface cutaneous immuneâ€related adverse events associated with <scp>antiâ€PD</scp>â€1 therapy resemble acute graft versus host disease more than lichen planus. Journal of Cutaneous Pathology, 2022, 49, 701-708.	1.3	4

#	Article	IF	Citations
37	Degradable polymers for gene delivery. , 2009, 2009, 2412-5.		3
38	Which Nanobasics Should Be Taught in Medical Schools?. AMA Journal of Ethics, 2019, 21, E337-346.	0.7	3
39	Postherpes zoster programmed death-1 inhibitorâ˜associated zosteriform granulomatous reactions. JAAD Case Reports, 2020, 6, 1201-1204.	0.8	3
40	Actinic Keratosis Color and Its Associations: A Retrospective Photographic, Dermoscopic, and Histologic Evaluation. Dermatologic Surgery, 2022, 48, 57-60.	0.8	3
41	Immunoengineering: Biodegradable Nanoellipsoidal Artificial Antigen Presenting Cells for Antigen Specific Tâ€Cell Activation (Small 13/2015). Small, 2015, 11, 1612-1612.	10.0	2
42	Lymphocyte Activation Gene 3 (LAG-3). , 2017, , 375-383.		1
43	Professional medical associations and the opportunity to promote breakthrough biomedical innovation. Drug Discovery Today, 2018, 23, 1453-1456.	6.4	1
44	Calciphylaxis Cutis Associated With Fibroblast Growth Factor Receptor (FGFR) Inhibitor Therapy: A New Challenge. Cureus, 2022, 14, e21478.	0.5	1
45	Molecular Characteristic of Variant and Classic Hairy Cell Leukemia.. Blood, 2008, 112, 1063-1063.	1.4	0
46	Lymphocyte Activation Gene 3 (LAG-3). , 2014, , 1-9.		0